18588-50-6

Basic information

• Product Name: 6-Methyl-5-phenyl-2,4-pyrimidinediamine
• Synonyms: 6-Methyl-5-phenyl-2,4-pyrimidinediamine
• CAS NO: 18588-50-6
• Molecular Formula: C₁₁H₁₂N₄
• Molecular Weight: 200.27
• Mol File: 18588-50-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 327.97°C (rough estimate)
• Flash Point: 244.9°C
• Appearance: /
• Density: 1.2007 (rough estimate)
• Vapor Pressure: 1.16E-07mmHg at 25°C
• Refractive Index: 1.4260 (estimate)
• CAS DataBase Reference: 6-Methyl-5-phenyl-2,4-pyrimidinediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methyl-5-phenyl-2,4-pyrimidinediamine(18588-50-6)
• EPA Substance Registry System: 6-Methyl-5-phenyl-2,4-pyrimidinediamine(18588-50-6)

Safety Data

• Hazardous Substances Data: 18588-50-6(Hazardous Substances Data)

Usage

Description

6-Methyl-5-phenyl-2,4-pyrimidinediamine, also known as MX-1938, is a pyrimidine derivative with potential pharmaceutical applications. It is a chemical compound known for its inhibitory effects on certain enzymes, making it a promising candidate for the development of novel therapeutic agents. Its unique chemical structure and potential biological activity have attracted interest in the pharmaceutical industry for further research and development.

Uses

Used in Pharmaceutical Industry:
6-Methyl-5-phenyl-2,4-pyrimidinediamine is used as a pharmaceutical agent for its potential therapeutic effects in treating various diseases. Its ability to selectively inhibit specific enzyme targets makes it a promising candidate for the development of novel treatments.
Used in Cancer Treatment:
In the field of oncology, 6-Methyl-5-phenyl-2,4-pyrimidinediamine is used as an anticancer agent. Its inhibitory effects on certain enzymes can potentially contribute to the suppression of tumor growth and the management of cancer progression.
Used in Neurodegenerative Disorders:
6-Methyl-5-phenyl-2,4-pyrimidinediamine is also being investigated for its potential use in the treatment of neurodegenerative disorders. Its enzyme-inhibiting properties may offer new avenues for therapeutic intervention in conditions such as Alzheimer's disease and Parkinson's disease.
Used in Drug Development Research:
In the research and development sector, 6-Methyl-5-phenyl-2,4-pyrimidinediamine serves as a subject of interest for scientists exploring its potential applications and mechanisms of action. Its unique chemical structure and biological activity provide a foundation for designing new drugs and understanding their interactions with biological systems.

InChI:InChI=1/C11H12N4/c1-7-9(8-5-3-2-4-6-8)10(12)15-11(13)14-7/h2-6H,1H3,(H4,12,13,14,15)

Upstream product

• 4468-48-8 1-phenyl-1-cyanopropan-2-one 
• 50-01-1 guanidine hydrochloride 
• 22211-32-1 3-Methoxy-2-phenyl-cis-crotononitril 
• 113-00-8 guanidine nitrate 
• 506-93-4 guanidine nitrate 
• 186581-53-3 diazomethane 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES

A method of treating a lysosomal storage disease comprises administering a pyrimethamine derivative to a subject in need thereof.

Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine resistant Plasmodium falciparum

The reduced binding of pyrimethamine to Serl08Asn (S108N) mutants of parasite dihydrofolate reductase (DHFR), which forms the basis of resistance of Plasmodium falciparum to pyrimethamine, is largely due to steric constraint imposed by the bulky side chain of N108 on Cl of the 5-p-Cl-phenyl group. This and other S108 mutants with bulky side chains all showed reduced binding to pyrimethamine and cycloguanil. Less effect on binding to some bulky mutants was observed for trimethoprim, with greater flexibility for the 5-substituent. S108N DHFR also binds poorly with other pyrimethamine derivatives with bulky groups in place of the p-Cl, and the binding was generally progressively poorer for the double (C59R+S108N) mutant. Removal of the p-Cl or replacement with m-Cl led to better binding with the mutant DHFRs. Pyrimethamine analogues with unbranched hydrophobic 6-substituents showed generally good binding with the mutant DHFRs. A number of compounds were identified with high affinities for both wild-type and mutant DHFRs, with very low to no affinity to human DHFR. Some of these compounds show good antimalarial activities against pyrimethamine-resistant P. falciparum containing the mutant DHFRs with low cytotoxicity to three mammalian cell lines.